SCYNEXIS INC SCYX
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
5/9
Piotroski F — financial health
-13.88
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $20.6M | -$8.6M | — | — | $49.4M |
| 2024 | $3.7M | -$21.3M | — | — | $55.1M |
| 2023 | $140.1M | $67.0M | — | — | $73.0M |
| 2022 | $5.1M | -$62.8M | — | — | $3.2M |
| 2021 | $13.2M | -$32.9M | — | -$54.6M | $41.3M |
| 2020 | $0 | -$55.2M | — | -$49.4M | $22.8M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Angulo Gonzalez David | Chief Executive Officer | 2026-04-01 | Buy | 108,695 | — |
| Macleod ivor | Chief Financial Officer | 2026-01-29 | Grant | 129,833 | — |
| Sukenick Scott | Chief Legal Officer | 2026-01-29 | Grant | 129,833 | — |
| Angulo Gonzalez David | Chief Executive Officer | 2026-01-29 | Grant | 391,333 | — |
| Angulo Gonzalez David | Chief Executive Officer | 2025-10-17 | Grant | 32,500 | $0.76 |
| Tinmouth Brian Philippe | director | 2025-06-26 | Grant | 23,000 | — |
| Macdonald Guy | director | 2025-06-26 | Grant | 23,000 | — |
| HASTINGS DAVID C | director | 2025-06-26 | Grant | 23,000 | — |
Why these scores methodology →
Piotroski F-score: 5/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -13.88 (distress)
- Working capital / assets 0.587
- Retained earnings / assets -6.525
- EBIT / assets -0.272
- Equity / liabilities 5.116
Source: SEC EDGAR filings · CIK 0001178253 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.